BeOne Medicines Ltd
Company Profile
Business description
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Contact
c/o BeOne Medicines I GmbH
94 Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12,000
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,161.10 | 45.30 | -0.49% |
| CAC 40 | 8,235.98 | 23.62 | -0.29% |
| DAX 40 | 23,742.44 | 61.51 | -0.26% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,582.96 | 17.57 | -0.17% |
| HKSE | 25,660.85 | 232.69 | -0.90% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,942.22 | 1,439.45 | 2.55% |
| NZX 50 Index | 13,043.40 | 23.22 | 0.18% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,967.80 | 46.20 | -0.51% |
| SSE Composite Index | 3,988.56 | 0.00 | 0.00% |